Nexus gets FDA nod for generic Trisenox
Nexus Pharmaceuticals has received the Food and Drug Administration's blessing for arsenic trioxide injection, a generic version of Teva’s Trisenox.
The generic Trisenox, which is available in 10 mg per 10 mL vial for injection, is indicated for relapsed or refractory acute promyelocytic leukemia.
“The approval of generic arsenic trioxide injection continues to show Nexus’s commitment in providing access to affordable critical-need generic injectables,” Nexus chief commercial officer Omair Ahmed said. “Collectively, as drug manufacturers and healthcare providers, we have a commitment to patients to ensure they are receiving affordable drugs they need, when they need them, which is why we make it our highest priority to be a reliable partner in supplying critical-need drugs.”
The generic Trisenox, which is available in 10 mg per 10 mL vial for injection, is indicated for relapsed or refractory acute promyelocytic leukemia.
“The approval of generic arsenic trioxide injection continues to show Nexus’s commitment in providing access to affordable critical-need generic injectables,” Nexus chief commercial officer Omair Ahmed said. “Collectively, as drug manufacturers and healthcare providers, we have a commitment to patients to ensure they are receiving affordable drugs they need, when they need them, which is why we make it our highest priority to be a reliable partner in supplying critical-need drugs.”